Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy Based on Database Data in Real-world Japanese Therapeutic Practice

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03205137

Enrollment

Registered

2017-07-02

Start date

2022-06-01

Completion date

2022-07-11

Last updated

2022-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The primary objective of this study is to compare the medication adherence measured by PDC of patients with FDC or double-pill combination therapy in real-world Japanese therapeutic practice.The further objective of this study is how much influence the background of patients to the adherence.

Interventions

DRUGsubjects treated with telmisartan/hydrochlorothiazide

subjects treated with telmisartan/hydrochlorothiazide

DRUGSubjects treated with Telmisartan and amlodipine

Subjects treated with Telmisartan and amlodipine

DRUGsubjects treated with Telmisartan+hydrochlorothiazide double-pill combination group

subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group

DRUGsubjects treated with telmisartan+amlodipine double pill

subjects treated with telmisartan+amlodipine double pill

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with hypertension * Patients must have their first prescription (defined as index date\*) for telmisartan and hydrochlorothiazide or Micombi® between 01/07/2010 and 28/09/2010 * Patients must have their first prescription (defined as index date\*) for telmisartan and amlodipine or Micamlo® between 10/12/2010 and 09/03/2011 * Patients must have at least 180 days follow up verified by the presence of prescription record

Exclusion criteria

* Patients who were under 40 years old at the time of enrolment * Patients who prescribed the study drugs less than 90 days during a follow up period of 180 days * Patients whose visits are less than 2 times during a follow up period of 180 days

Design outcomes

Primary

Measure	Time frame
Proportion of days covered of patients treated with single- and double- combination therapy	180 days

Secondary

Measure	Time frame
Demographic and clinical characteristics of patients treated with single- and double combination	180 days

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026